ADMA Biologics Inc (NASDAQ: ADMA) stock closed at $8.81 on 5/10/24 after a major increase of 27.1%. Moreover, trading volume in this advance was exceptionally high at 420% of normal. The stock has risen 30.7% during the last week and has been exceptionally strong relative to the market over the last nine months.
Current PriceTarget Research Rating
Reflecting future returns on capital that are forecasted to be above the cost of capital, ADMA is expected to be a major Value Builder.
ADMA Biologics has a current Value Trend Rating of B (Positive). With this rating, PTR’s two proprietary measures of a stock’s current attractiveness are providing inconsistent signals. ADMA Biologics has a neutral Appreciation Score of 42 but a very high Power Rating of 98, and the Positive Value Trend Rating results.
Rating Review
In light of this very positive price change we are reviewing our current Overall Rating of B. This review will be completed in the next several days.
Be the first to comment